Intratumoral and Peritumoral Radiomics of Contrast-Enhanced CT for Prediction of Disease-Free Survival and Chemotherapy Response in Stage II/III Gastric Cancer

作者：Junmeng Li, Chao Zhang, Jia Wei, Peiming Zheng, Hui Zhang, Yi Xie, Junwei Bai, Zhonglin Zhu, Kangneng Zhou, Xiaokun Liang, Yaoqin Xie, Tao Qin · 发表于：Frontiers in Oncology · 年份：2020 · DOI：10.3389/fonc.2020.552270 · 被引用次数：37 · 研究领域：Gastric Cancer Management and Outcomes、Radiomics and Machine Learning in Medical Imaging、Cholangiocarcinoma and Gallbladder Cancer Studies

BACKGROUND: We evaluated the ability of radiomics based on intratumoral and peritumoral regions on preoperative gastric cancer (GC) contrast-enhanced CT imaging to predict disease-free survival (DFS) and chemotherapy response in stage II/III GC. METHODS: This study enrolled of 739 consecutive stage II/III GC patients. Within the intratumoral and peritumoral regions of CT images, 584 total radiomic features were computed at the portal venous-phase. A radiomics signature (RS) was generated by using support vector machine (SVM) based methods. Univariate and multivariate Cox proportional hazards models and Kaplan-Meier analysis were used to determine the association of the RS and clinicopathological variables with DFS. A radiomics nomogram combining the radiomics signature and clinicopathological findings was constructed for individualized DFS estimation. RESULTS: <0.0001). Multivariate analysis showed that the RS was an independent predictor of DFS. The signature had a higher predictive accuracy than TNM stage and single radiomics features and clinicopathological factors. Further analysis showed that stage II/III patients with high scores were more likely to benefit from adjuvant chemotherapy. CONCLUSION: The newly developed radiomics signature was a powerful predictor of DFS in GC, and it may predict which patients with stage II and III GC benefit from chemotherapy.